- Open
- 0.15
- High
- 0.15
- Low
- 0.14
- Close
- 0.15
- Change
- -0.01 (-6.67%)
- Volume
- 9,733,856
| 25 Aug 2026 | 07:00:03 | Appointment of Chairman |
| 19 Aug 2026 | 07:00:03 | NXP002 Development Update |
| 28 May 2026 | 07:00:03 | Half Year Report |
| 31 Mar 2026 | 07:00:01 | Total Voting Rights |
| 11 Mar 2026 |
| 23 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 3 Feb 2025 | Annual Report and Accounts (to 2024-09-30) | |
| 19 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company specializes in discovering and developing novel drug forms with improved physical properties, particularly its lead program NXP002, which is an inhaled treatment for progressive fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis. Nuformix operates primarily in the preclinical stage, targeting markets in the United States and Europe, and aims to secure licensing or collaborative agreements to advance its product pipeline.
| 25 Aug 2026 | 07:00:03 | Appointment of Chairman |
| 19 Aug 2026 | 07:00:03 | NXP002 Development Update |
| 28 May 2026 | 07:00:03 | Half Year Report |
| 31 Mar 2026 | 07:00:01 | Total Voting Rights |
| 11 Mar 2026 |
| 23 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 3 Feb 2025 | Annual Report and Accounts (to 2024-09-30) | |
| 19 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company specializes in discovering and developing novel drug forms with improved physical properties, particularly its lead program NXP002, which is an inhaled treatment for progressive fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis. Nuformix operates primarily in the preclinical stage, targeting markets in the United States and Europe, and aims to secure licensing or collaborative agreements to advance its product pipeline.
| 07:00:07 |
| £1.0 million Placing |
| 21 Aug 2026 |
| Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video) |
| 19 Aug 2026 | Nuformix gains 19% in London trade on positive NXP002 study ahead of ERS Congress |
| 19 Aug 2026 | Nuformix reports positive NXP002 inhalation study results |
| 28 May 2026 | Nuformix strengthens financial position and advances NXP002 programme |
| 10 Mar 2026 | Nuformix shares jump 12.5% as FDA grants orphan drug status for rare lung disease programme |
| 07:00:07 |
| £1.0 million Placing |
| 21 Aug 2026 |
| Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video) |
| 19 Aug 2026 | Nuformix gains 19% in London trade on positive NXP002 study ahead of ERS Congress |
| 19 Aug 2026 | Nuformix reports positive NXP002 inhalation study results |
| 28 May 2026 | Nuformix strengthens financial position and advances NXP002 programme |
| 10 Mar 2026 | Nuformix shares jump 12.5% as FDA grants orphan drug status for rare lung disease programme |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £32m | — | |
| £21m | -0.7% | |
| £19m | -0.4% | |
| £7m | -0.7% | |
| £3m | -0.9% | |
NFXNuformix plc | £3m | +0.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £32m | — | |
| £21m | -0.7% | |
| £19m | -0.4% | |
| £7m | -0.7% | |
| £3m | -0.9% | |
NFXNuformix plc | £3m | +0.0% |
